Abstract

The two estrogen receptor (ER) subtypes, ERα and ERβ, belong to the nuclear receptor superfamily. The human ERβ variant ERβ2 is proposed to be expressed at higher levels than ERβ1 in many breast tumors and it has been suggested that ERβ2, in contrast to ERβ1, is associated with aggressive phenotypes of various cancers. However, the role of endogenous ERβ2 in breast cancer cells remains elusive. In this study, we identified that triple negative breast cancer (TNBC) cell lines express endogenous ERβ2, but not ERα or ERβ1. This allows novel studies of endogenous ERβ2 functions independent of ERα and ERβ1. We show that overexpression of ERβ2 in TNBC cells increased whereas knockdown of endogenous ERβ2 decreased cell proliferation and cell invasion. To elucidate the molecular mechanism responsible for these cellular phenotypes, we assayed ERβ2 dependent global gene expression profiles. We show that ERβ2 decreases prolyl hydroxylase 3 (PHD3) gene expression and further show that this is associated with increased hypoxia inducible factor 1α (HIF-1α) protein levels, thus providing a possible mechanism for the invasive phenotype. These results are further supported by analysing the expression of ERβ2 and PHD3 in breast tumor samples where a negative correlation between ERβ2 and PHD3 expression was observed. Together, we demonstrate that ERβ2 has an important role in enhancing cell proliferation and invasion, beyond modulation of ERβ and ERβ1 signalling which might contribute to the invasive characteristics of TNBC. The invasive phenotype could potentially be mediated through transcriptional repression of PHD3 and increased HIF-1α protein levels.

Highlights

  • Breast cancer is the most frequently diagnosed cancer among women in industrialized countries [1]

  • We show that estrogen receptor beta isoform 2 (ERβ2) decreases prolyl hydroxylase 3 (PHD3) gene expression and further show that this is associated with increased hypoxia inducible factor 1α (HIF-1α) protein levels, providing a possible mechanism for the invasive phenotype

  • We screened the expression of ERβ2 in a panel of ten breast cancer cell lines, including four estrogen receptor (ER)-positive luminal (MCF-7, MDA-MB-175, ZR-751, CAMA-1), two human epidermal growth factor receptor 2 (HER2)-positive (SK-BR-3 and HCC1569) and four triple negative breast cancer (TNBC) (Hs578T, MDA-MB-231, BT549 and BT20) cell lines

Read more

Summary

Introduction

Breast cancer is the most frequently diagnosed cancer among women in industrialized countries [1]. TNBC accounts for approximately 15 to 20% of all breast cancers and is often more aggressive with higher rates of recurrence and more frequent distant metastasis than other types of breast cancer [3]. Due to a lack of targeted therapy options available to subgroups that express ERα or with HER2 amplification, cytotoxic chemotherapy is the systemic therapy currently available for TNBC patients [4, 5]. ERs belong to the nuclear receptor protein superfamily of ligand-activated transcription factors [6, 7]. The ERβ protein that shares the domain structure of other nuclear receptors is referred to as the full length wild type ERβ or ERβ1. ERβ2 lacks an intact ligand binding domain and activation function 2 (AF-2). Since ERβ2 has an intact DNA-binding domain and an intact N-terminal domain, including the AF-1 region, it could be involved in gene regulation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call